Dilafor Licenses Tafoxiparin to Exeltis in $100M+ Potential Deal
Event summary
- Dilafor signs binding term sheet with Exeltis for exclusive semi-global license (excluding China/Japan) of tafoxiparin for labor priming.
- Exeltis to fund all future development and commercialization, including pivotal Phase 3 trials.
- Deal includes sales-based milestone payments and up to double-digit royalties on net sales.
- Karolinska Development holds 32% ownership in Dilafor (3% direct, 29% indirect).
The big picture
The deal reflects growing demand for labor induction solutions amid rising maternal-fetal risks in prolonged pregnancies. Exeltis's global footprint in women's health positions tafoxiparin for potential blockbuster status if clinical and commercial milestones are met. Karolinska Development stands to benefit from its minority stake in Dilafor, though the immediate financial impact on its portfolio valuation is minimal.
What we're watching
- Clinical Success
- Whether tafoxiparin clears Phase 3 trials and secures regulatory approval.
- Commercial Execution
- Exeltis's ability to commercialize tafoxiparin in high-induction markets.
- Valuation Impact
- How milestone and royalty payments affect Karolinska Development's stake in Dilafor.
Related topics